The 3-month PDUFA delay removes a near-term catalyst and introduces execution risk. Monitor for any further FDA requests or competitor developments. The stock may trade lower on the delay, but the lack of approvability concerns limits downside. Watch for updates on the August 24, 2026 PDUFA date.
BIIB drugs
BIIB drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $192.75entry
- T+1 · 6mo ago +2.38%α +2.14% · $197.33
- T+5 · 6mo ago −0.71%α −2.18% · $191.37
- T+20 · 5mo ago +1.35%α +1.32% · $195.34
- T+60 · 3mo ago +4.71%α +1.99% · $201.82
Price Chart
How similar events traded
Executive Summary
Biogen and Eisai announced a 3-month FDA review extension for the sBLA of LEQEMBI IQLIK (once-weekly subcutaneous injection) as a starting dose for early Alzheimer's disease, pushing the PDUFA date to August 24, 2026. The FDA requested additional information, classifying it as a major amendment, but has not raised approvability concerns. This delay introduces uncertainty around the launch timeline for the subcutaneous formulation, which is key to expanding patient access and convenience.
Key Facts
- FDA extended review period by 3 months for LEQEMBI IQLIK subcutaneous starting dose sBLA
- New PDUFA action date is August 24, 2026 (previously May 2026)
- FDA classified the additional information request as a major amendment
- FDA has not raised any concerns regarding approvability to date
- Subcutaneous maintenance dosing was already approved on August 26, 2025
- LEQEMBI is approved in over 50 countries worldwide
Financial Impact
Delay of up to 3 months in potential approval of subcutaneous starting dose, which could affect adoption ramp and revenue trajectory for LEQEMBI IQLIK. No specific financial figures provided.
Risk Factors
- Further FDA requests could extend review beyond August 2026
- Competing Alzheimer's treatments may gain market share during delay
- Adoption of subcutaneous formulation may be slower if approval is further delayed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290827 |
Track record
34 reports on BIIB
10 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers